Jpmorgan Chase & CO Forma Therapeutics Holdings, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.12 - $20.24 $3.72 Million - $10.6 Million	522,232 Added 2423.46%	543,781 $10.8 Million
Q2 2022 Aug 11, 2022	SELL	$5.1 - $10.0 $581 - $1,140	-114 Reduced 0.53%	21,549 $148,000
Q1 2022 May 11, 2022	BUY	$8.34 - $14.69 $35,328 - $62,226	4,236 Added 24.31%	21,663 $202,000
Q4 2021 Feb 10, 2022	SELL	$13.6 - $24.89 $77,887 - $142,545	-5,727 Reduced 24.73%	17,427 $248,000
Q3 2021 Nov 12, 2021	BUY	$21.22 - $25.7 $491,327 - $595,057	23,154 New	23,154 $536,000

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.